Billing Code Overview

HCPCS Level II code J0585 represents an injectable formulation: Injection, onabotulinumtoxina, 1 unit. This code is used for billing the drug product itself when onabotulinumtoxinA is administered for therapeutic purposes. The service type is drug administration / therapeutic injection, and the typical site of service is the outpatient setting (for example, physician office, POS 11).

Clinical Context

A patient with focal dystonia (for example, blepharospasm or cervical dystonia) presents to an outpatient physician office (POS 11) for targeted chemodenervation. A neurology or physiatry evaluation documents focal involuntary muscle contractions causing functional impairment. The clinician discusses risks, benefits, and expected onset/duration of effect. On the day of service, the patient is positioned, target muscles are identified by examination (and optional EMG localization if indicated), and onabotulinumtoxinA is reconstituted per manufacturer guidance. The clinician administers one or more injections into the affected muscles and bills for the drug units administered using HCPCS Level II code J0585 (injection, onabotulinumtoxina, 1 unit), along with an appropriate procedure code for the injection service when required. The encounter includes documentation of indication, informed consent, units administered, injection sites, lot number, and any discarded drug amount if applicable.

Coding Specifications

• Modifiers

• JW — Use when a portion of the drug is discarded and not administered to any patient; report the discarded units in addition to the units administered when payer policy requires separate reporting.

• 59 — Use to indicate a Distinct Procedural Service when a separate, identifiable service or procedure is performed on the same day and it is appropriate under payer rules to indicate distinctness from other services billed.

• Associated Provider Taxonomies

• Notes on usage

• HCPCS Level II code J0585 reports medication units of onabotulinumtoxinA; the drug administration encounter may require an appropriate injection or chemodenervation procedure code for the actual service depending on payer policy.

• When reporting discarded drug, append modifier JW to the specific drug line as required. Modifier 59 is appended to separate procedure codes when the service meets distinct procedural criteria per payer guidance.

Related Diagnoses

• G11.4 — Hereditary spastic paraplegia

Uses of onabotulinumtoxinA may relate to focal spasticity management in affected muscles causing functional impairment.

• G24.1 — Genetic torsion dystonia

Botulinum toxin injections can be used to reduce focal dystonic muscle overactivity associated with this diagnosis.

• G24.2 — Idiopathic nonfamilial dystonia

Focal chemodenervation with onabotulinumtoxinA is a therapeutic option for symptomatic control of dystonic movements.

• G24.3 — Spasmodic torticollis

Cervical dystonia (spasmodic torticollis) is a common indication for targeted botulinum toxin injections to affected neck muscles.

• G24.4 — Idiopathic orofacial dystonia

Orofacial muscle chemodenervation may be performed to relieve dystonic contractions impacting speech or eating.

• G24.5 — Blepharospasm

Periocular injections of onabotulinumtoxinA are commonly used to treat involuntary eyelid closure from blepharospasm.

• G24.8 — Other dystonia

Covers additional dystonic presentations where focal botulinum toxin injections may be clinically relevant.

• G24.9 — Dystonia, unspecified

Used when dystonia is present but not further specified; onabotulinumtoxinA may be applied for symptomatic control.

• G25.3 — Myoclonus

Focal myoclonic activity may be treated with chemodenervation in select cases to reduce involuntary jerks.

• G25.89 — Other specified extrapyramidal and movement disorders

Includes other movement disorder presentations where targeted botulinum toxin injections can be considered for symptom management.

• G36.1 — Acute and subacute hemorrhagic leukoencephalitis [Hurst]

Secondary focal hypertonicity or dystonic features in the recovery phase may lead to localized injection therapy.

• G36.8 — Other specified acute disseminated demyelination

Focal motor abnormalities from demyelinating processes can occasionally be addressed with targeted chemodenervation.

• G37.0 — Diffuse sclerosis of central nervous system

Spastic or dystonic focal muscle overactivity in chronic CNS disease may be an indication for injections.

• G37.1 — Central demyelination of corpus callosum

Focal movement disturbances secondary to central demyelination can be managed symptomatically with botulinum toxin units reported with J0585.

• G37.2 — Central pontine myelinolysis

Residual focal motor disturbances after central pontine injury may lead to localized chemodenervation interventions.

Related Codes

• Common workflow relationships: the procedural CPT/HCPCS injection codes above define the service/approach and are commonly billed in conjunction with a drug supply line reporting units of onabotulinumtoxinA using HCPCS Level II code J0585. Some codes may be alternatives depending on anatomical site and clinical indication.

National mean rates for HCPCS Level II code J0585 show a large gap between Medicare/average commercial benchmarks and Aetna. Medicare and BUCA (average commercial) share a mean of $67.29, while Aetna's mean rate is markedly higher at $226.11; Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare all have mean rates clustered near $7.50 or lower.

Dispersion measured as the difference between the 75th and 25th percentiles is tightest for Cigna Health (0.00) and UnitedHealthcare (0.00), indicating very concentrated reported rates. Blue Cross Blue Shield and BUCA have modest dispersion (0.50 and 1.50 respectively). Aetna shows the widest dispersion at 4.00. The table and chart below present the full breakdown.